Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1313439 | 0.97 | ALDH1A1 (0.37) | CYP4F2CYP4A11ALDH1A1FKBP1AMEN1 | |
| SCHEMBL1315266 | 0.96 | ALDH1A1 (0.39) | CYP4F2CYP4A11ALDH1A1FKBP1AMEN1 | |
| SCHEMBL1312804 | 0.94 | CYP4F2 (0.38) | CYP4F2CYP4A11FKBP1AMEN1KMT2A | |
| SCHEMBL1313228 | 0.78 | CYP4F2 (0.42) | CYP4F2CYP4A11ALDH1A1MEN1KMT2A | |
| SCHEMBL12121686 | 0.73 | CYP4F2 (0.41) | CYP4F2CYP4A11ALDH1A1FKBP1AMEN1 | |
| SCHEMBL6893301 | 0.72 | CYP4F2 (0.46) | CYP4F2CYP4A11ALDH1A1MEN1KMT2A | |
| SCHEMBL1265697 | 0.72 | CYP4F2 (0.46) | CYP4F2CYP4A11ALDH1A1MEN1KMT2A | |
| SCHEMBL1316123 | 0.72 | CYP4F2 (0.40) | CYP4F2CYP4A11ALDH1A1MEN1KMT2A | |
| SCHEMBL12121692 | 0.70 | ALDH1A1 (0.41) | CYP4F2CYP4A11ALDH1A1FKBP1AMEN1 | |
| SCHEMBL1313060 | 0.70 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331541-B1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-04-22 | — | — | EP | disclosed |
| EP-2331541-B1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-04-22 | — | — | EP | disclosed |
| US-8618300-B2 | Indolizine inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| US-20110275627-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| US-20110275627-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| WO-2010027762-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275627-A1 | INDOLIZINE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTB4R2, LTC4S | CYP4F2 379/4885CYP4A11 44/4885ALDH1A1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.